You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The prospective study will combine real-world, clinical, and genomic data to streamline lung cancer clinical trials and find treatment-response biomarkers.
The method, called representative sequencing, homogenizes chunks of leftover tumor tissue following pathology extraction to capture an unbiased profile of the tumor's cellular heterogeneity.
Investigators reported on detection rates for cancers and precancers in a group of 350 individuals presenting for standard of care colonoscopy.
The Shanghai-based molecular diagnostics firm is working with the Shanghai Zhongshan Hospital and other medical centers to enroll patients into the PREDICT trial.
Researchers found that 61 percent of patients they analyzed carried germline pathogenic or likely pathogenic variants in candidate cancer predisposition genes.
The group said the recommendations aim to standardize and improve warfarin response genotyping assays.
The German hospital will build interpretation and reporting on the PierianDx Clinical Genomics Workspace for two Illumina assays.
Investigators from the Friends of Cancer Research's tumor mutational burden harmonization project shared new data this week at AACR's virtual meeting.
The two UK companies are validating GeneFirst's assay for use with Rapid Dx's Rapid Minilab RT-PCR Desktop Point of Care Platform.
As part of the deal, Applied DNA will permanently place robotic and diagnostic equipment at the hospital to enable validation of the test.
The firms will evaluate Stratafide, a pan-solid tumor diagnostic test designed to identify actionable genomic alterations in tissue or blood samples.
The study suggests that pediatric low-grade gliomas driven by genetic rearrangements tend to be diagnosed earlier and have better outcomes than those driven by SNVs.
Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
The precision medicine center at Colorado's UCHealth expects to add 100,000 participants annually and have 17 drug-gene pairs for pharmacogenomics this year.
The health system said that the program is encouraging patient compliance and increasing revenues and savings.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
The clinics see patients whose overall health may benefit from learning about their genetic predisposition for certain medical conditions.
After pilot programs showed patients and physicians are interested in genomics, NorthShore is working on "hardwiring" genetics into routine care.
The insurer will cover testing at the Rady Children's Institute for Genomic Medicine for children in intensive care with unexplained medical conditions.
Nearly 3,500 patients were referred to the Roberts Individualized Medical Genetics Center for exome sequencing or other testing during the clinical program's first four years.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.